PHIO (Phio Pharmaceuticals) Moat Score: 1/10 (As of Jul. 11, 2026)


PHIO Phio Pharmaceuticals Corp PHIO
28 GF Score
Price $1.02
! 1 Warning Sign
View Full Analysis

What is Phio Pharmaceuticals Moat Score?

Phio Pharmaceuticals PHIO -0.97% 28 Moat Score is 1 as of Jul. 11, 2026. GuruFocus rates PHIO with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Phio Pharmaceuticals ranks worse than 52.33% on this metric.

Phio Pharmaceuticals has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Phio Pharmaceuticals has No Moat: Phio Pharmaceuticals has minimal market presence and lacks significant intellectual property or customer loyalty. Its competitive advantages are transient and not sustainable.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Phio Pharmaceuticals might have No Moat - Very weak/transient advantages.

Phio Pharmaceuticals  (NAS:PHIO) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Phio Pharmaceuticals Moat Score Related Terms

PHIO vs PBM, KPRX, OSRH: Moat Score Comparison

For the Biotechnology subindustry, Phio Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phio Pharmaceuticals Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Moat Score falls into.


PHIO
28GF Score
Phio Pharmaceuticals Corp PHIO
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Phio Pharmaceuticals (PHIO) has a Moat Score of 1 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Phio Pharmaceuticals ranks #730 out of 1395 companies in the Biotechnology industry, placing it in the top 52.3%.
Is Phio Pharmaceuticals' Moat Score too high?
Phio Pharmaceuticals' current Moat Score is 1. The Biotechnology industry median Moat Score is 2.00. Phio Pharmaceuticals' value of 1 is 50% below this industry median. Based on the distribution chart, Phio Pharmaceuticals ranks #730 out of 1395 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Phio Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Phio Pharmaceuticals' Moat Score compare to PBM and KPRX?
According to the Biotechnology industry distribution chart, Phio Pharmaceuticals ranks #730 out of 1395 companies for Moat Score. This places Phio Pharmaceuticals in the lower half of its industry. The industry median Moat Score is 2.00. Phio Pharmaceuticals' value of 1 is 50% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Phio Pharmaceuticals's current Moat Score of 1 is 50% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Phio Pharmaceuticals's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phio Pharmaceuticals stock overvalued right now?
Phio Pharmaceuticals (PHIO) has a current Moat Score of 1. The current Moat Score is 1 and 50% below the Biotechnology industry median of 2.00. Phio Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Phio Pharmaceuticals (PHIO), the current Moat Score is 1 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Phio Pharmaceuticals Business Description

Address 411 Swedeland Road, Suite 23-1080, King of Prussia, PA, USA, 19406
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
28GF Score

Get the complete analysis for PHIO

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price